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Background: Anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements have been reported in
2-13% of patients with non-small cell lung cancer (NSCLC). Patients with ALK rearrangements do not respond to
EGFR-specific tyrosine kinase inhibitors (TKIs); however, they do benefit from small molecule inhibitors
targeting ALK.
Results: In this study, fluorescence in situ hybridization (FISH) using a break-apart probe for the ALK gene
was performed on formalin fixed paraffin-embedded tissue to determine the incidence of ALK rearrangements
and hybridization patterns in a large unselected cohort of 1387 patients with a referred diagnosis of
non-small cell lung cancer (1011 of these patients had a histologic diagnosis of adenocarcinoma). The
abnormal FISH signal patterns varied from a single split signal to complex patterns. Among 49 abnormal
samples (49/1387, 3.5%), 32 had 1 to 3 split signals. Fifteen samples had deletions of the green 50 end of the
ALK signal, and 1 of these 15 samples showed amplification of the orange 30 end of the ALK signal. Two
patients showed a deletion of the 30ALK signal. Thirty eight of these 49 samples (38/1011, 3.7%) were among
the 1011 patients with confirmed adenocarcinoma. Five of 8 patients with ALK rearrangements detected by
FISH were confirmed to have EML4-ALK fusions by multiplex RT-PCR. Among the 45 ALK-rearranged samples
tested, only 1 EGFR mutation (T790M) was detected. Two KRAS mutations were detected among 24 ALK-
rearranged samples tested.
Conclusions: In a large unselected series, the frequency of ALK gene rearrangement detected by FISH was
approximately 3.5% of lung carcinoma, and 3.7% of patients with lung adenocarcinoma, with variant signal
patterns frequently detected. Rare cases with coexisting KRAS and EGFR mutations were seen.
Keywords: ALK rearrangement, ALK amplification, FISH, KRAS, EGFR, Non-small cell lung cancer,
Adenocarcinoma, Crizotinib* Correspondence: Zunyan.X.Dai@questdiagnostics.com
1Department of Cytogenetics, Quest Diagnostics Nichols Institute, 14225
Newbrook Drive, Chantilly, VA 20151, USA
Full list of author information is available at the end of the article
© 2012 Dai et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Dai et al. Molecular Cytogenetics 2012, 5:44 Page 2 of 6
http://www.molecularcytogenetics.org/content/5/1/44Background
Lung cancer is the leading cause of cancer-related deaths
in the US with an estimated 160,000 deaths attributed to
lung cancer in 2012 [1]. Histologically, the World Health
Organization (WHO) classifies lung cancer into non-
small cell lung cancer (NSCLC, 85%) and small-cell lung
cancer (15%). NSCLC is further divided into three major
subgroups: adenocarcinoma, squamous cell carcinoma,
and a less well-characterized group of large cell carcin-
oma (40%, 30% and 15% of all lung cancer cases in the
United States, respectively). Based on the patient’s med-
ical status and stage of disease, there are four general
treatment strategies, including surgery, radiation ther-
apy, chemotherapy, and/or targeted therapy. The use of
targeted kinase inhibitors is based on the presence of
specific genetic alterations, such as activating mutations
in the epidermal growth factor receptor (EGFR) or acti-
vating chromosomal fusions involving the ALK kinase,
and can be highly effective if the tumors harbor these
associated molecular alterations [2]. Therefore, molecu-
lar tests are routinely performed to identify mutations in
oncogenes in lung cancer, including EGFR and ALK; to
identify those patients with a high likelihood of response
to targeted therapy; and reduce unnecessary side effects
of ineffective treatments. The mutation status of KRAS
is usually also assessed since tumors that show such
mutations do not respond to targeted kinase therapies.
ALK gene rearrangements have been reported in 2% to
13% of patients with NSCLC [2]. Most patients with
ALK rearrangements typically have adenocarcinomas
and are younger patients with minimal to no smoking
history. ALK-rearranged tumors typically lack EGFR and
KRAS mutations. Recent studies have demonstrated that
lung cancers harboring ALK rearrangements do not re-
spond to EGFR-specific tyrosine kinase inhibitors, but
benefit from a small molecule inhibitor targeting the
ALK kinase (ie, crizotinib [XalkoriW, Pfizer, Inc.]).
Fluorescence in situ hybridization (FISH) with a
multicolor break-apart ALK probe is the currently
FDA-approved method for screening for ALK gene rear-
rangements (Figure 1A). Exon-scanning reverse-tran-
scription PCR methods have also been developed.
Inversion of the short arm of chromosome 2 is the most
common rearrangement associated with the ALK gene in
lung cancer. This rearrangement leads to fusion between
the 50 end of the echinoderm microtubule-associated pro-
tein-like 4 (EML4) gene (located at 2p21) and the 30 end
of the ALK gene (at 2p23): the EML4-ALK fusion. Alter-
nate ALK FISH signal patterns which may indicate other
activating rearrangements also occur and are studied here.
The reasons for the variability in the detection fre-
quency of ALK gene rearrangements in NSCLC could be
due to a variety of technical and biologic influences.
These include biases due to small sample size, variationsin the performance and interpretation of ALK FISH
studies, and the relative proportions of smoking-related
cases which usually lack both EGFR and ALK mutations.
In a prior large screening study, ALK rearrangement was
detected in 5.5% of 1500 cases of NSCLC [3]. In this
study, we examined the frequency and patterns of ALK
rearrangements in clinical specimens from a large cohort
of lung cancer patients from both primary and tertiary
settings across the United States referred for molecular
profiling.Results
ALK FISH was performed on an unselected series that
included 1387 samples from patients with NSCLC.
Overall, 49 of the 1387 tumor samples (3.5%) had altered
ALK signals. Thirty eight of these 49 samples (38/1011,
3.7%) were from patients with confirmed adenocarcin-
omas (Table 1). In 32 cases, there was the expected pat-
tern of one split orange and green signal indicative of an
ALK gene rearrangement and one single fusion signal
from the intact ALK gene (Figure 1B). Among variant
signals, the most commonly seen (15 cases) was deletion
of the 50ALK (green signal, Figure 1C). More complex
FISH patterns included normal split patterns along with
loss of the 50 signal; this was often seen in tumors that
showed gains of intact ALK signals consistent with
polysomy (Figure 1D).
One of the 15 patients with deletion of the 50ALK, also
showed 5-25 copies of the 30ALK (high level amplifica-
tion, Figure 1E). Two samples showed a deletion of the
30ALK (orange signal, Figure 1F). According to the new
FDA-approved Vysis FISH ALK break-apart probe kit
guidelines, patients with deletion of the 30ALK split sig-
nal should be considered negative for rearrangements,
because the tyrosine kinase domain of ALK is located in
the 30 region of the ALK gene.
To investigate the significance of variant signal pat-
terns, we also performed exon scanning multiplex RT-
PCR to identify EML4-ALK fusion transcripts in a subset
of both typical and variant cases. Five of these samples
(3 with break apart and 2 with loss of 50ALK) were con-
firmed positive for EML4-ALK fusion. Among these, one
was positive for fusion variant 1, one for variant 3a, and
two for both variants 3a and 3b. These are the most
common ALK fusion variants reported by other investi-
gators [2]. In addition, new transcription variants were
identified, derived from a fusion of EML4 exon 17 to the
30 end portion of ALK exon 20 with two different small
insertions (Figure 2 for gene structures and putative pro-
teins, and Additional file 1 for nucleotide sequences and
amino acid sequences). The 3 samples that did not show
EML4-ALK fusion by PCR had FISH patterns with dele-
tion of the 50ALK probe.
B. Split ALK  signal A. ALK  FISH probe  
2pter 5’3’
ALK at 2p23 
~442kb ~300kb 
C. Loss of 5’ green signal D. Split and loss of 5’  
loss of 5’split 
F. Loss of 3’ orange signal E. loss of 5’ signal and
amplification of 3’ signal 
Figure 1 FISH analysis with the ALK dual-color break-apart probe shows variable rearrangement patterns. A) The FDA approved break-
apart FISH probe (Abbott Molecular) at 2p23 to detect ALK rearrangements. The 50 end of the ALK gene is labeled with SpectrumGreen and the 30
end of the ALK gene is labeled with SpectrumOrange. B) Samples had 1 to 3 split signals. C) Deletion of the green 50 end of the ALK signal.
D) Coexistence of polysomy, split signal, and deletion of the 50 end of the ALK signal. E) Malignant cells in one patient with adenocarcinoma
showing deletion of the 50 end of the ALK signal and amplification of the 30 end signals. F) Two patients showed a deletion of the orange 30
signal and considered negative for an ALK rearrangement.
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mutations in exons 18-21 of the EGFR gene, only one
mutation, T790M, was detected in a patient with a typi-
cal positive break-apart FISH signal pattern of the ALK
gene. Two KRAS mutations were detected among 24
ALK-positive samples examined, G12F in a patient with
a deletion of the green 50 end of the ALK signal andG13C in the sample that showed amplification of the
30ALK region (Figure 1E).
Discussion
In this study, the frequency of ALK gene rearrangements
detected using a dual-color break-apart FISH probe was
3.7% of adenocarcinoma cases. This is somewhat lower
Table 1 Frequency of ALK rearrangements in lung cancer
patients
All patients Adenocarcinoma as
submitting diagnosis
ALK rearrangement 49a 38b
Total cases 1387 1011
% ALK rearrangement 3.5% 3.7%
a One patient had large cell carcinoma and 10 patients were diagnosed as
carcinomas without further typing. Two of the 49 patients had a deletion of 30
end signal, which should be regarded as negative for ALK rearrangement. bOne
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Figure 2 Characterization of novel EML4-ALK transcription variants in
positive break-apart FISH signal pattern of the ALK gene. A) Two transcripti
the 30 end portion of ALK exon 20, with 46 base pairs deleted from the 50 e
gene rearrangement with either a 23-nucleotide or a 6-nucleotide insertion
transcripts. The transcript with an insertion of 23 nucleotides produced a tr
an early stop codon. However, the transcript with an insertion of 6 nucleot
region of EML4 and the C-terminal region of ALK with the protein tyrosine
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patients, but close to 3.9% which was observed in two
cohorts of 720 and 1121 lung adenocarcinomas from
two series in Japan [4,5]. Our results are consistent with
previous studies where ALK rearrangements have been
largely (but not completely) restricted to adenocarcin-
omas that lack EGFR or KRAS mutations.
Here, we show that the ALK FISH signal patterns may
vary from a single split signal to very complex signal pat-
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a patient with lung adenocarcinoma. This patient had a typical
on variants were detected, derived from a fusion of EML4 exon 17 to
nd of ALK exon 20. These two fusion transcripts were from the same
from EML4 intron 17. B) Putative proteins from EML4-ALK fusion
uncated EML4 protein and no EML4-ALK fusion protein, as a result of
ides produced an EML4-ALK fusion protein, containing the N-terminal
kinase domain (PTKc).
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were observed simultaneously in some samples likely due
to intratumoral heterogeneity. Although polysomy of
chromosome 2 did occur frequently in NSCLC (and was
not regarded as evidence of an ALK-specific rearrange-
ment), high-level amplification of the ALK fusion signal
was a rare event.
The current study and a previous report using the
same PCR method [6] showed correlation between PCR
and FISH for detection of EML4-ALK fusions even when
loss of 50 green signals was seen. In our study, 5 samples
(3 with break apart and 2 with loss of 50ALK) were
positive for an EML4-ALK fusion by multiplex RT-
PCR. This is similar to a previous study that an EML4-
ALK fusion was detected by RT-PCR in 22 out of 31
patients with FISH-positive ALK rearrangements [3].
However, FISH also detected variant ALK signal pat-
terns in three cases that were negative for EML4-ALK
fusion by PCR; this may be indicative of translocations
involving ALK and genes other than EML4 [3], or
other mechanisms of ALK activation. The general cor-
relation between the two methods supports using loss
of the 50ALK signal as presumptive evidence of an ALK
gene rearrangement.
EML4-ALK and other 2p23/ALK gene rearrangements
lead to a constitutively activated ALK kinase, which con-
fers sensitivity of NSCLC tumors to ALK inhibitors [3].
Lung cancer patients with ALK rearrangements have
been shown to have significant reductions in tumor bur-
den in response to treatment with the ALK inhibitor cri-
zotinib, which led to its accelerated FDA approval in the
United States in 2011 [3,7,8]. Crizotinib has also been
shown to have activity against the 1-2% of patients with
NSCLC that show rearrangements of another receptor
tyrosine kinase gene, ROS1, located at 6q22 [5,9].
Patients who harbor ALK rearrangements do not benefit
from treatment with the EGFR-specific tyrosine kinase
inhibitors showing that the EGFR inhibition is bypassed.
The clinical behavior of NSCLC cases with variant ALK
signal patterns is less clear. Amplification of the ALK fusion
has been seen in a patient undergoing crizotinib therapy
[10] and may be a sign of developing resistance. But the
response of untreated NSCLC with ALK gene amplification
is not yet clear. Given the large number of signaling path-
ways that are influenced by ALK fusion products [7], the
behavior and appropriate treatment of NSCLC cases that
have variant ALK signal patterns also require further study.Conclusions
Use of a break-apart ALK FISH probe is an effective
method for assessing ALK gene rearrangement status in
routinely submitted formalin fixed paraffin-embedded
NSCLC tumor samples from a wide variety of tissuesources and clinical settings. Variant ALK FISH signals
usually, but not always, represent EML4 –ALK fusions.Methods
Patient samples
Samples from 1387 lung cancer patients (1011 with a
submitting diagnosis of adenocarcinoma) were included
in this study. Most were small transbronchial biopsies,
or cell blocks of lymph node aspirates or malignant
pleural or pericardial effusions. These samples were con-
secutively submitted for ALK rearrangement testing. The
presence of lung cancer cells was verified by pathological
examination of a hematoxylin-eosin-stained section adja-
cent to the slide used for FISH analysis. Mutation stud-
ies for EGFR and KRAS were also performed if sufficient
tumor was available, as was EML4-ALK RT-PCR.ALK FISH
FISH using a dual-color break-apart probe for ALK was
performed on paraffin-embedded tissue sections according
to the Vysis ALK Break Apart FISH Probe Kit protocol
(Abbott Molecular, Des Plaines, IL), using the BX51/BX52
Olympus fluorescence microscope (Olympus, Richardson,
TX). The SenSysW CCD camera (Photometrics, Tucson,
AZ) was used to capture selected images. The occurrence
of an ALK rearrangement (ALK positive) was concluded
if >15% of tumor cells showed split orange and green sig-
nals and/or deletion of green signals; otherwise, the speci-
men was classified as negative for ALK rearrangement.
EGFR and KRAS mutations
Sanger sequencing of dissected lung cancer samples
was performed to detect mutations in EGFR and KRAS.
DNA was PCR amplified for exons 18-21 of EGFR
and exons 1 and 2 of KRAS. The PCR products were
purified and sequenced on a DNA sequencer (ABI;
Carlsbad, CA).
Exon scanning RT-PCR for EML4-ALK fusion transcripts
RNA was extracted from formalin fixed paraffin-
embedded sections, reverse transcribed and PCR ampli-
fied using one-step RT-PCR kit and products detected
using fragment analysis on ABI 3730 genetic analyzer, as
previously described [6]. The assay utilized 22 EML4
exon primers and a single ALK reverse primer to detect
a variety of inversion variants. Fusion types were identi-
fied based on expected sizes of the PCR products, with
the new variant identified by standard dideoxy chain-
termination DNA sequencing of the abnormally-sized
cDNA PCR product, as described [6].
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Additional file 1: Dai et. al., Supplemental data for nucleotide
sequences and putative amino acid sequences of new EML4-ALK
transcription variants in a patient with lung adenocarcinoma.
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